AKT1 and breast carcinoma: In ER+ breast cancers, activation of the PI3K/PTEN/Akt/mTORC1 pathway can result in both estrogen-dependent and estrogen-independent ER activity and contribute to estrogen-independence and potentially loss of sensitivity to hormonal based therapies.